Why the study?
Does the use of methylprednisolone in the cardiopulmonary bypass prime improve clinical outcomes or increase adverse events in pediatric patients undergoing cardiac surgery?
Population
525 pediatric patients undergoing cardiac surgery with cardiopulmonary bypass at a single center.
Comparison
Methylprednisolone included in the… vs No methylprednisolone in the cardiopulmonary…
Design
Cohort
Authors
Loading...
No benefit from routine methylprednisolone in pediatric CPB prime; leaves open selective use pending randomized trials.
Does the use of methylprednisolone in the cardiopulmonary bypass prime improve clinical outcomes or increase adverse events in pediatric patients undergoing cardiac surgery?
Elimination of methylprednisolone from the cardiopulmonary bypass prime in pediatric cardiac surgery did not worsen clinical outcomes but reduced the incidence of postoperative wound infections and respiratory failure requiring tracheostomy.
Dreher et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: